anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVES: We previously revealed the role of tanshinone IIA (TAN IIA) on endothelial cells and the impact of TAN IIA on the endothelial-to-mesenchymal transition in systemic sclerosis (SSc). In this study, we sought to further determine whether TAN IIA can directly act on the skin fibroblasts of scleroderma and look into its underlying anti-fibrotic mechanisms.
METHODS: Bleomycin was used to establish the SSc mouse model. After TAN IIA treatment, dermal thickness, type I collagen and hydroxyproline content were measured. Primary fibroblasts were acquired from SSc patients and cultured in vitro, and the effects of TAN IIA on proliferation, apoptosis and the cell cycle of fibroblasts were detected.
RESULTS: In a bleomycin-induced SSc model, we discovered that TAN IIA significantly improved skin thickness and collagen deposition, demonstrating a potent anti-fibrotic action. TAN IIA inhibits the proliferation of skin fibroblasts derived from SSc patients by causing G2/M cell cycle arrest and promoting apoptosis. Additionally, TAN IIA downregulated extracellular matrix gene transcription and collagen protein expression in skin fibroblasts in a dose-gradient-dependent manner. Furthermore, we showed how TAN IIA can reduce the activation of the transforming growth factor-β (TGF-β)/Smad and mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathways, which are important factors in SSc.
CONCLUSIONS: In summary, these data suggest that TAN IIA can reduce SSc-related skin fibrosis by modulating the TGF-β/Smad and MAPK/ERK signalling pathways. More importantly, our results imply that TAN IIA can directly act on the skin fibroblasts of SSc, therefore, inhibiting fibrosis.
Herein, we propose a paper-based laboratory via enzyme-free nucleic acid amplification and nanomaterial-assisted cation exchange reactions (CERs) assisted single-cell-level analysis (PLACS). This method allowed for the rapid detection of mucin 1 and trace circulating tumor cells (CTCs) in the peripheral blood of lung cancer patients. Initially, an independently developed method requiring one centrifuge, two reagents (lymphocyte separation solution and erythrocyte lysate), and a three-step, 45 min sample pretreatment was employed. The core of the detection approach consisted of two competitive selective identifications: copper sulfide nanoparticles (CuS NPs) to C-Ag+-C and Ag+, and dual quantum dots (QDs) to Cu2+ and CuS NPs. To facilitate multimodal point-of-care testing (POCT), we integrated solution visualization, test strip length reading, and a self-developed hand-held fluorometer readout. These methods were detectable down to ag/mL of mucin 1 concentration and the single-cell level. Forty-seven clinical samples were assayed by fluorometer, yielding 94% (30/32) sensitivity and 100% (15/15) specificity with an area under the curve (AUC) of 0.945. Nine and 15 samples were retested by a test strip and hand-held fluorometer, respectively, with an AUC of 0.95. All test results were consistent with the clinical imaging and the folate receptor (FR)-PCR kit findings, supporting its potential in early diagnosis and postoperative monitoring.
BACKGROUND: Inadequate DNA damage repair promotes aberrant differentiation of mammary epithelial cells. Mammary luminal cell fate is mainly determined by a few transcription factors including GATA3. We previously reported that GATA3 functions downstream of BRCA1 to suppress aberrant differentiation in breast cancer. How GATA3 impacts DNA damage repair preventing aberrant cell differentiation in breast cancer remains elusive. We previously demonstrated that loss of p18, a cell cycle inhibitor, in mice induces luminal-type mammary tumors, whereas depletion of either Brca1 or Gata3 in p18 null mice leads to basal-like breast cancers (BLBCs) with activation of epithelial-mesenchymal transition (EMT). We took advantage of these mutant mice to examine the role of Gata3 as well as the interaction of Gata3 and Brca1 in DNA damage repair in mammary tumorigenesis.
RESULTS: Depletion of Gata3, like that of Brca1, promoted DNA damage accumulation in breast cancer cells in vitro and in basal-like breast cancers in vivo. Reconstitution of Gata3 improved DNA damage repair in Brca1-deficient mammary tumorigenesis. Overexpression of GATA3 promoted homologous recombination (HR)-mediated DNA damage repair and restored HR efficiency of BRCA1-deficient cells. Depletion of Gata3 sensitized tumor cells to PARP inhibitor (PARPi), and reconstitution of Gata3 enhanced resistance of Brca1-deficient tumor cells to PARP inhibitor.
CONCLUSIONS: These results demonstrate that Gata3 functions downstream of BRCA1 to promote DNA damage repair and suppress dedifferentiation in mammary tumorigenesis and progression. Our findings suggest that PARP inhibitors are effective for the treatment of GATA3-deficient BLBCs.
The method involves acquiring two two-dimensional (2D) images of a region of a human body, using a digital camera. The two 2D images are acquired respectively before and after applying a skin care product or make-up product on the region. Two three-dimensional (3D) images (F1, F2) are obtained by transforming an altitude of grey levels of the respective 2D images. The 3D images are displayed and compared. Independent claims are also included for the following: (a) a make-up kit or treatment kit for a region of a human body (b) a hosting server of a computer site e.g. Internet site, arranged to compare aspects of a region of a human body at two different instants.
Patients receive everolimus PO QD on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
Infertility is a disease of the male or female reproductive system, defined by the failure to achieve a pregnancy after 12 months or more of regular unprotected sexual intercourse (WHO).

Large numbers of people are affected by infertility in their lifetime, according to a new report published by World Health Organization. Around 17.5% of the adult population - roughly 1 in 6 worldwide - experience infertility. The inability to conceive children is experienced as a stressful situation by individuals and couples all around the world. The consequences of infertility are manifold and may include societal repercussions and personal emotional suffering. The infertile couple experienced greater dissatisfaction with themselves and their marriages. Females experienced greater discontent over time and had greater emotional problems than males because infertility had traditionally been viewed as a women problem and women have been expected to suffer greater emotional problems due to infertility. Treatment for infertility provides an opportunity for women and men to become parents. The evolution of assisted reproductive technology (ART) for the treatment of infertile couples is considered an extraordinary restorative accomplishment throughout the world. However accessibility of treatments such as IVF is limited to only those who can afford to pay out of pocket (OOP). Even among those who have the ability to pay, their willingness and financial ability to undergo multiple cycles of ART often depends on OOP payments incurred. However, due to the desire for a child, couples are often ready to make significant financial sacrifices often beyond their means. Couples are frequently willing to suffer catastrophic financial hardship instead of forgoing infertility care, resulting in negative economic consequences. Evidence suggests that in the absence of mechanisms for risk protection, OOP payments can push households into poverty.
BACKGROUND: Rotational vertebrobasilar artery syndrome, or bow hunter syndrome, is a rare yet well-documented pathology. This study presents a surgical approach to a latent manifestation of dynamic, extension-only, bilateral codominant vertebral artery compression in the V3 segment, associated with craniocervical instability and central canal stenosis.
METHODS: The clinical presentation involves the treatment of positional vertigo resulting from left and high-grade right vertebral artery stenosis during neck extension only. Diagnosis was confirmed through a formal angiogram under provocative maneuvers. Surgical intervention, detailed in this section, employed a multidisciplinary approach, including intraoperative angiograms to ensure patent vertebral arteries precraniocervical fusion.
RESULTS: The surgical treatment demonstrated success in addressing extension-only vertebrobasilar syndrome and associated complications of C1-2 pannus and craniocervical instability. Intraoperative angiograms confirmed vertebral artery patency pre- and postsurgical positioning, ensuring the effectiveness of the multidisciplinary approach.
CONCLUSIONS: This study concludes by highlighting the successful multidisciplinary surgical treatment of a patient with nonunion of a C1 Jefferson fracture, leading to extension-only vertebrobasilar syndrome complicated by C1-2 pannus and craniocervical instability. The importance of considering vertebral artery dynamic stenosis in cases of positional vertigo or transient neurological symptoms following an injury is emphasized. Surgical stabilization, particularly when conservative measures prove ineffective, is recommended, with careful attention to pre- and postsurgical positioning to verify vertebral artery patency and posterior vasculature integrity.
Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes and carboplatin IV over 1-2 hours on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
PURPOSE:To promote enteral colonization of useful bacteria, by obtaining the title composition, consisting of live microbial cells of useful bacteria consisting of bacteria belonging to the genus Bifidobacterium and/or lactic acid bacteria and lactoferrin and useful for suppressing and preventing diarrhea and administering an effective amount thereof. CONSTITUTION:The subject composition consisting of live microbial cells consisting of bacteria belonging to the genus Bifidobacterium and/or lactic acid bacteria and lactoferrin. Live microbial cell powder is prepared by adding a dispersion to a solution of microbial cells obtained by culturing in a large amount and freeze-drying the resultant mixture. The lactoferrin is a protein, binding to iron and present in cow's or human milk and can be powdered by separating and purifying the lactoferrin from the cow's or human milk with an adsorbent resin and freeze-drying the resultant substance. The subject composition can be administered in the form of powder, tablet and solution or added to a food or feed and administered. The composition is preferably used in a dose so as to provide >=10<6> live microbial cells/day and >=1mg/day lactoferrin based on 1kg body weight.
ABSTRACT      This invention comprises animal derived cells, especially erythrocytes, which have been artificially modified (and referred to as enginerred erythrocytes or RBCs) so as to incorporate in their plasma membranes an antigen, CD4 protein derived from lymphocytes which will cause them to selectively seek out and fuse with other cells that are infected with a virus, especially the AIDS virus.  These modified cells can be further altered so as to contain in their cytoplasm a cytotoxic agent which, after the cell has fused with a target cell, will result in the pooling of their respective cytoplasms and the death of both cells, with subsequent removal by the reticuloendothelial system.  The invention also includes the production and use of similarly modified liposomes. The present invention can be used a treatment of Acquired Immune Deficiency Syndrome (AIDS), e.g. where the antigen on the modified cell is advantageously the CD4 antigen of animal lymphocytes and the target cell is an animal cell infected with the AIDS virus.  This invention also relates to treatment of disease conditions, especially viral diseases and most notably AIDS, by injecting into a patient so afflicted a therapeutically effective amount of antigenically modified cells containing a cytotoxic substance.  Such modified cells and liposomes can also be used as a basis for an in vitro diagnostic assay involving cells derived from the blood of patients suspected of having AIDS.
Participants will perform a twelve-week training intervention in addition to their usual care as provided by the memory clinics where the patients are recruited. The training intervention will be prescribed according to a newly developed exergame-based intervention concept that consists of an individually adapted multi-domain exergame-based simultaneous cognitive-motor training with incorporated cognitive tasks that will be adopted with a deficit-oriented focus on the neurocognitive domains of (1) learning and memory, (2) executive function, (3) complex attention, and (4) perceptual-motor function.
Provided is a dentin regenerative cell culture 4 that can bring about the rapid regeneration of dentin in a deficit region 5. In the treatment of a tooth 1 using the dentin regenerative cell culture 4 according to the present invention, a root canal filler 3 containing dental pulp stem cells is filled into a root canal where a pulpectomy has been performed (FIG. 1a). The dentin regenerative cell culture 4 is then implanted in a deficit region 5 of the dentin 1a, and temporary sealing with a packing 6 is carried out. The dentin regenerative cell culture 4 forms three-dimensionally in conformity with the shape of the deficit region 5 with the coalescence of cell masses 10 of a plurality of odontoblasts, and thus the dentin regeneration is well promoted. In addition, gaps between the dentin regenerative cell culture 4 and biological tissue can be rapidly filled. Infection due to bacterial infiltration can thereby be prevented.
NEW MATERIAL:The 1,4-dihydropyridine derivative of formula I (R is 1-6C straight-chain, branched chain or cyclic saturated or unsaturated hydrocarbon group; Ar<1> and Ar<2> are aryl which may be substituted with alkyl, etc.; A is 3-6C straight-chain, branched chain or cyclic unsaturated aliphatic hydrocarbon group) and its acid addition salt. EXAMPLE:4-(3-Nitrophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarbo xylic acid 3-methyl ester 5-cinnamyl ester. USE:It has strong vasodilating and hypotensive activities, and is useful as a remedy for hypertension. It has extremely excellent activity, and keeps the activity for a long period. The development of the peak of the hypotensive effect is delayed, and the compound exhibits mild hypotensive activity. PREPARATION:The compound of formula I can be prepared e.g. by reacting the compounds of formula II, formula III and formula IV at 50-150 deg.C.
A temporary tattoo kit containing a sheet assembly having a temporary tattoo. The assembly may include multiple sheets that include at least one sheet with a celebrity tattoo design and is packaged in a container. A method of assembling a temporary tattoo kit is also included with the steps of obtaining a license from an owner of a celebrity tattoo design. The next step requires manufacturing a sheet assembly that includes at least one celebrity design and packaging the assembly within a container. Further, the invention also includes a method of selling and distributing a temporary tattoo. Locations for sale and distribution may include the use of a self serve kiosk machine that may be located at a variety of different locations such as gas stations, airports, and retail stores.
The research will involve a clinical evaluation consisting of 100 patients in the prostate cohort. It will assess changes in five different ultrasound spectroscopic parameters over different times during treatment with radiotherapy as predictors of tumour shrinkage and pathologic complete response. Ultrasound parameters investigated will include mid-band fit (related to image intensity), spectroscopic slope (backscatter versus frequency), spectroscopic intercept, histogram fit size and shape parameters which can be used as estimates of scatterer size and concentration.
In all patients, both impacted lower third molars are surgically removed in one session, beginning the extractions in the right side. Subsequently, one of the alveolus will be irrigated with 4ml of bupivacaine 0.5% with adrenaline vasoconstrictor 1: 200,000 (BUPIROP® 0.5% ROPSOHN THERAPEUTICS SAS), the contralateral alveolus will be irrigated with 4 ml of saline solution 0.9% (Baxter laboratories) prior to the placement of the suture for the closure of the surgical wound, using the aspiration to avoid the exit of the medication out of the alveolus.
### Adverse Events Resulting In Discontinuation Of Treatment 

In placebo-controlled, parallel-group clinical trials in the elderly, 3.8% of 208 patients who received placebo, 2.3% of 215 patients who received 2 mg LUNESTA, and 1.4% of 72 patients who received 1 mg LUNESTA discontinued treatment due to an adverse event. In the 6-week parallel-group study in adults, no patients in the 3 mg arm discontinued because of an adverse event. In the long-term 6-month study in adult insomnia patients, 7.2% of 195 patients who received placebo and 12.8% of 593 patients who received 3 mg LUNESTA discontinued due to an adverse event. No event that resulted in discontinuation occurred at a rate of greater than 2%. 

### Adverse Events Observed At An Incidence Of ≥2% In Controlled Trials 

Table 1 shows the incidence of treatment-emergent adverse events from a Phase 3 placebo-controlled study of LUNESTA at doses of 2 or 3 mg in non-elderly adults. Treatment duration in this trial was 44 days. The table includes only events that occurred in 2% or more of patients treated with LUNESTA 2 mg or 3 mg in which the incidence in patients treated with LUNESTA was greater than the incidence in placebo-treated patients. 

Adverse events from Table 1 that suggest a dose-response relationship in adults include viral infection, dry mouth, dizziness, hallucinations, infection, rash, and unpleasant taste, with this relationship clearest for unpleasant taste. 

Table 2 shows the incidence of treatment-emergent adverse events from combined Phase 3 placebo-controlled studies of LUNESTA at doses of 1 or 2 mg in elderly adults (ages 65-86). Treatment duration in these trials was 14 days. The table includes only events that occurred in 2% or more of patients treated with LUNESTA 1 mg or 2 mg in which the incidence in patients treated with LUNESTA was greater than the incidence in placebo-treated patients. 

Adverse events from Table 2 that suggest a dose-response relationship in elderly adults include pain, dry mouth, and unpleasant taste, with this relationship again clearest for unpleasant taste. 

These figures cannot be used to predict the incidence of adverse events in the course of usual medical practice because patient characteristics and other factors may differ from those that prevailed in the clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatments, uses, and investigators. The cited figures, however, do provide the prescribing physician with some basis for estimating the relative contributions of drug and non-drug factors to the adverse event incidence rate in the population studied.
BACKGROUND: Despite representing over half of all pediatric patella fractures, inferior pole patellar sleeve fractures (PSFs) are a relatively uncommon pediatric injury. As a result, existing literature on PSFs is limited to case reports and small case series. The purpose of this study was to evaluate the radiographic and clinical characteristics of operatively treated PSFs as well as outcomes following surgical management.
METHODS: A retrospective review of all inferior pole PSFs requiring surgery from 2007 to 2023 was performed at a single urban tertiary care children's hospital. Cases were identified using diagnostic and billing codes. Patient demographics, injury characteristics, surgical techniques, and postoperative rehabilitation practices were recorded. Regional skeletal maturity, fracture characteristics, and postreduction patellar height were recorded. Postoperative complications were recorded and categorized using the modified Clavien-Dindo Classification System (CDS).
RESULTS: Thirty-eight inferior pole PSFs were identified meeting study criteria. The majority of patients were male (86.8%), and the mean age at injury was 11.0 years (range: 7.2 to 15.0). Mean BMI was 21.1. Radiographically, the majority of patients were Epiphyseal Fusion Stage 0 (nonunion), with a median postreduction Caton-Deschamps index (CDI) of 1.2 (IQR: 1.1 to 1.3). These fractures were predominantly treated with suture-based fixation (84%). Postoperative immobilization varied within the cohort, and the initiation of knee ROM was permitted at a median of 3.5 (IQR: 2.0 to 4.6) weeks. All patients regained full range of motion and straight leg raise without extensor lag, and return-to-sport was achieved by a median of 17.6 weeks (IQR: 12.8 to 30.3). Complications occurred in 10 (26.3%) patients, with 3 (7.9%) requiring a return to the OR (CDS Grade III).
CONCLUSIONS: Inferior pole PSFs appear to occur most commonly among prepubertal males of normal BMI and normal patellar height. Despite variable rehabilitation protocols, operative management resulted in restoration of extensor mechanism function. Eight percent of patients experienced complications requiring unplanned surgery. This large series improves our understanding of the epidemiology, injury characteristics, and postoperative outcomes of an operatively treated cohort of a rare injury pattern.
LEVEL OF EVIDENCE: Level IV.
Preterm rupture of the membranes (PROM) is the leading identifiable cause of prematurity and accounts for about one-third of all preterm deliveries and 18-20% of perinatal deaths in the USA. When PROM occurs at very early gestational ages, the clinician must make a decision whether to attempt to prolong the pregnancy or whether to recommend prompt delivery. Both approaches carry substantial risk. The strategy of continuing the pregnancy is commonly called "expectant management." During expectant management, gestational age steadily increases, and the balance naturally shifts toward favoring delivery. Once the gestational age reaches 34 weeks, the risk of lethal or permanent sequelae of prematurity or minimal, so most clinicians agree that delivery is warranted. Despite an attempt at expectant management, the majority of patients with PROM will be delivered within the first week or so. Unfortunately, no intervention other than antibiotic prophylaxis or corticosteroids have been shown to prolong latency or reduce neonatal morbidity after PROM. Recent evidence suggests that prophylactic administration of progesterone medications may reduce the risk of preterm delivery in women with certain risk factors, notably those with a history of a prior preterm delivery and those with a shortened cervix discovered by ultrasound examination. Clearly, women with PROM are at very high risk of preterm delivery, so there is a pressing need to study whether 17 hydroxyprogesterone caproate (17P) is effective after PROM. Progesterone might be beneficial after PROM both because it tends to promote uterine quiescence by suppressing the formation of myometrial gap junctions and because it has anti-inflammatory properties, suppressing the production of inflammatory cytokines and thereby inhibiting cervical ripening. Inflammation is a major pathway leading to preterm labor, cervical dilation \& preterm delivery. 17P would seem to be like an ideal candidate for prolongation of pregnancy after PROM.

This is a double-blinded, placebo-controlled, multicenter, randomized clinical trial of 17P versus placebo. The primary outcome measure will be the percentage of each group reaching either a gestational age of 34w0d or documentation of fetal lung maturity at 32w0d to 33w6d. Secondary outcomes will include the latency period for each group and the percentage of newborns in each group who have major neonatal morbidity or death.